Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.

Zhou G, Liu A, Hu X, Qi G, Zhang Y

Medicine1 Mar 2026

PMID41894290PMCIDPMC13034935DOI10.1097/md.0000000000048123PepBankPUB-41894290

Summary

This study aimed to evaluate the efficacy and safety of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure with preserved ejection fraction (HFpEF). This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group. The intervention duration was 24 weeks. The primary endpoints included changes in N-terminal pro-B-type natriuretic peptide levels, 6-minute walk distance, and cardiac structural parameters. Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes. After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups. In terms of metabolic indicators, the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05). The incidence of major cardiovascular composite endpoints in the combination group was lower than that in the monotherapy groups (P < .05). The overall incidence of adverse events was similar among the 3 groups (P > .05). Dapagliflozin combined with liraglutide has a synergistic effect in improving cardiac function and metabolic disorders in obese patients with HFpEF, with good safety, providing a more effective therapeutic strategy for clinical practice.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In obese patients with HFpEF, adding liraglutide to dapagliflozin was associated with a greater decrease in B-type natriuretic peptide than dapagliflozin monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, adding liraglutide to dapagliflozin was linked to lower B-type natriuretic peptide than dapagliflozin alone.
Peptide
Liraglutide
Outcome
DecreaseB-type natriuretic peptide levels
Study
n = 240
Comparator
Dapagliflozin monotherapy
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
The primary endpoints included changes in N-terminal pro-B-type natriuretic peptide levels, 6-minute walk distance, and cardiac structural parameters.
Show in the study text Report a problemFND-4189429007
02HumanObservational studyEfficacy outcome
In obese patients with HFpEF, adding liraglutide to dapagliflozin was associated with greater 6-minute walk-distance improvement than dapagliflozin monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, adding liraglutide to dapagliflozin was linked to greater walking improvement than dapagliflozin alone.
Peptide
Liraglutide
Outcome
Increase6-minute walk distance
Study
n = 240
Comparator
Dapagliflozin monotherapy
Analysis
Primary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
The primary endpoints included changes in N-terminal pro-B-type natriuretic peptide levels, 6-minute walk distance, and cardiac structural parameters.
Show in the study text Report a problemFND-4189429008
03HumanObservational studyEfficacy outcome
In obese patients with HFpEF, adding liraglutide to dapagliflozin was associated with greater weight loss than dapagliflozin monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, adding liraglutide to dapagliflozin was linked to greater weight loss than dapagliflozin alone.
Peptide
Liraglutide
Outcome
DecreaseWeight
Study
n = 240
Comparator
Dapagliflozin monotherapy
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
In terms of metabolic indicators, the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes.
Show in the study text Report a problemFND-4189429009
04HumanObservational studyEfficacy outcome
In obese patients with HFpEF, adding liraglutide to dapagliflozin was associated with better blood glucose control than dapagliflozin monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, adding liraglutide to dapagliflozin was linked to better glucose control than dapagliflozin alone.
Peptide
Liraglutide
Outcome
Direction not reportedBlood glucose control
Study
n = 240
Comparator
Dapagliflozin monotherapy
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
In terms of metabolic indicators, the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes.
Show in the study text Report a problemFND-4189429010
05HumanObservational studyEfficacy outcome
In obese patients with HFpEF, adding liraglutide to dapagliflozin was associated with lower major cardiovascular composite endpoint incidence than dapagliflozin monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, adding liraglutide to dapagliflozin was linked to fewer major cardiovascular endpoints than dapagliflozin alone.
Peptide
Liraglutide
Outcome
DecreaseMajor cardiovascular composite endpoints
Study
n = 240
Comparator
Dapagliflozin monotherapy
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The incidence of major cardiovascular composite endpoints in the combination group was lower than that in the monotherapy groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Show in the study text Report a problemFND-4189429011

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with HFpEF, dapagliflozin plus liraglutide was associated with a greater decrease in B-type natriuretic peptide than liraglutide monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, dapagliflozin plus liraglutide was linked to lower B-type natriuretic peptide than liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseB-type natriuretic peptide levels
Study
n = 240
Comparator
Liraglutide monotherapy
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
The primary endpoints included changes in N-terminal pro-B-type natriuretic peptide levels, 6-minute walk distance, and cardiac structural parameters.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429001
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with HFpEF, dapagliflozin plus liraglutide was associated with greater 6-minute walk-distance improvement than liraglutide monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, dapagliflozin plus liraglutide was linked to greater walking improvement than liraglutide alone.
Peptide
Liraglutide
Outcome
Increase6-minute walk distance
Study
n = 240
Comparator
Liraglutide monotherapy
Analysis
Primary
Outcome group
Exercise and physical function · Cardiovascular
Source sentences
Summary
After 24 weeks of intervention, the combination group showed a more significant decrease in B-type natriuretic peptide levels (P < .05) and a greater improvement in 6-minute walk distance (P < .05) compared with the 2 monotherapy groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
The primary endpoints included changes in N-terminal pro-B-type natriuretic peptide levels, 6-minute walk distance, and cardiac structural parameters.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429002
08HumanNot a test of Liraglutide aloneObservational studySafety outcome
In obese patients with HFpEF, overall adverse-event incidence did not significantly differ among dapagliflozin plus liraglutide, dapagliflozin, and liraglutide after 24 weeks.
In plain wordsIn obese patients with HFpEF, adverse events did not significantly differ among dapagliflozin plus liraglutide, dapagliflozin alone, and liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeOverall adverse events
Study
n = 360
Comparator
Dapagliflozin plus liraglutide, dapagliflozin, or liraglutide
Analysis
Secondary
Outcome group
Adverse events · Whole body
Source sentences
Summary
The overall incidence of adverse events was similar among the 3 groups (P > .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429006
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with HFpEF, dapagliflozin plus liraglutide was associated with greater weight loss than liraglutide monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, dapagliflozin plus liraglutide was linked to greater weight loss than liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseWeight
Study
n = 240
Comparator
Liraglutide monotherapy
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In terms of metabolic indicators, the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429003
10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with HFpEF, dapagliflozin plus liraglutide was associated with better blood glucose control than liraglutide monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, dapagliflozin plus liraglutide was linked to better glucose control than liraglutide alone.
Peptide
Liraglutide
Outcome
Direction not reportedBlood glucose control
Study
n = 240
Comparator
Liraglutide monotherapy
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In terms of metabolic indicators, the combination group had greater weight loss (P < .05) and better blood glucose control (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
Summary · context
Secondary endpoints included metabolic indicators (weight, blood glucose, etc) and safety outcomes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429004
11HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with HFpEF, dapagliflozin plus liraglutide was associated with lower major cardiovascular composite endpoint incidence than liraglutide monotherapy after 24 weeks.
In plain wordsIn obese patients with HFpEF, dapagliflozin plus liraglutide was linked to fewer major cardiovascular endpoints than liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseMajor cardiovascular composite endpoints
Study
n = 240
Comparator
Liraglutide monotherapy
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The incidence of major cardiovascular composite endpoints in the combination group was lower than that in the monotherapy groups (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study enrolled 360 obese patients with HFpEF, who were divided into 3 groups according to different treatment methods: the combination group (dapagliflozin + liraglutide), the dapagliflozin group, and the liraglutide group, with 120 patients in each group.
Summary · context
The intervention duration was 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4189429005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.